U.S., March 4 -- ClinicalTrials.gov registry received information related to the study (NCT06853444) titled 'A Phase 1/2 Study of ESG206 in Patients with Primary Immune Thrombocytopenia' on Feb. 25.
Brief Summary: This is a multicenter, open-label Phase1/2 study aimed at evaluating the safety, tolerability, pharmacokinetic (PK) profile, pharmacodynamics (PD), immunogenicity, and preliminary efficacy of ESG206. The study will be conducted in patients with primary immune thrombocytopenia.
Study Start Date: March 25
Study Type: INTERVENTIONAL
Condition:
Immune Thrombocytopenia (ITP)
Intervention:
DRUG: ESG206
Administered via intravenous (IV) infusion
DRUG: ESG206
Administered via intravenous (IV) infusion
DRUG: ESG206
Administered...